🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  2. CARDIOASPIRIN 100 mg Compresse gastroresistenti, Tabex 1,5 mg tabletki powlekane

    Fondazione Telethon ETS

    Subjects at high risk of inflammatory state and mortality from lung cancer, other cancers and all causes

    phase 2 small molecule active

    1 trial

  3. CBD, ABILIFY 1 mg/ml oral solution, Aripiprazolo Aurobindo 15 mg compresse, ARIPIPRAZOLE , Composition (%w/V): Sesame oil, refined 90,00, Ethanol, anhydrous 7,91, Sucralose 0,05, DL-alfa-tocopheryl acetate 0,18, Raspberry flavor 0,02.

    Fondazione Telethon ETS

    Substance-Induced Psychosis

    phase 2 small molecule active

    1 trial

  4. CC-92480, Dexamethason acis 8 mg Tabletten, Dexamethason 8 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason 4 mg JENAPHARM®, Dexamethason-ratiopharm® 4 mg Tabletten

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  5. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  6. CD19-Targeted NEX-T CAR T, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, CYCLOPHOSPHAMIDE

    Celgene Europe Limited

    Lupus Nephritis, Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  7. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Common variable immunodeficiency

    phase 2 small molecule active

    1 trial

  8. CEMIPLIMAB

    Fondazione Telethon ETS

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  9. CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  10. CETUXIMAB , MK-1084, MK-1084, MK-1084, MK-1084

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  11. CETUXIMAB, FOLINIC ACID, FLUOROURACIL, IRINOTECAN

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  12. CIALIS 5 mg film-coated tablets

    The George Institute

    sexual/ erectile function in women and men after treatment for rectal cancer

    phase 2 small molecule active

    1 trial

  13. CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE

    The George Institute

    Extrahepatic cholangiocarcinoma (eCCA)

    phase 2 small molecule active

    1 trial

  14. CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  17. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  18. CM-24 and Nivolumab - Dose Escalation

    PURPLE BIOTECH LTD.

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  19. CM336 Plus Isatuximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  20. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  21. CPP-109 vigabatrin

    CATALYST PHARMACEUTICALS, INC.

    Methamphetamine Dependence

    phase 2 small molecule terminated

    1 trial

  22. CRIZOTINIB, CRIZOTINIB, XALKORI 200 mg hard capsules, CRIZOTINIB, CRIZOTINIB, CRIZOTINIB, XALKORI 250 mg hard capsules, Torisel 30 mg concentrate and solvent for solution for infusion

    Disc Medicine

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    phase 2 small molecule active

    1 trial

  23. CS-3150

    Daiichi Sankyo

    Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  24. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources